Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have earned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $44.71.
DNTH has been the subject of a number of recent research reports. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, August 12th. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.
View Our Latest Stock Report on DNTH
Institutional Investors Weigh In On Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
DNTH opened at $27.85 on Wednesday. The stock has a market capitalization of $817.37 million, a price-to-earnings ratio of -4.78 and a beta of 1.85. The company has a fifty day moving average of $27.91 and a 200 day moving average of $26.19. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. On average, equities research analysts forecast that Dianthus Therapeutics will post -2.32 earnings per share for the current year.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
- Five stocks we like better than Dianthus Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Learn Technical Analysis Skills to Master the Stock Market
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.